Key result
Subcutaneous cannabidiol attenuates fibrosis, hypertrophy, and LVEF decline in murine heart failure.
Why the study?
Does subcutaneous cannabidiol prevent heart failure dysfunction and remodeling in mice with heart failure?
Does subcutaneous cannabidiol prevent heart failure dysfunction and remodeling in mice with heart failure?
Answers are grounded in this paper and cite their sources.
In a preclinical mouse model of heart failure, cannabidiol attenuated cardiac remodeling and preserved contractile function by sustaining mitochondrial function and redox balance.
Heart failure (HF) is characterized by energy deprivation, calcium (Ca2+) handling alterations, and inflammation: effects associated with mitochondrial dysfunction. Cannabidiol previously prevented mitochondrial dysfunction. Thus, it may prevent HF progression. In mice with HF, subcutaneous cannabidiol attenuated cardiac fibrosis, hypertrophy, loss of ejection fraction, and inflammation; isolated cardiomyocytes preserved cell shortening, Ca2+ handling, mitochondrial function and redox balance. Hypertrophied ventricular cardiomyoblasts suggested cannabidiol-mediated effects through peroxisome proliferator-activated gamma receptors. Therefore, cannabidiol in HF limited cardiac hypertrophy and preserved contractile function by sustaining cardiomyocyte and mitochondrial function through redox balance maintenance, supporting cannabidiol role as a cardioprotective therapy in HF.
No takes yet. Share an insight, caveat, or question.
García‐Rivas et al. (2025) studied Heart failure. Cannabidiol was evaluated on Cardiac fibrosis, hypertrophy, loss of ejection fraction, and inflammation. Subcutaneous cannabidiol in mice with heart failure attenuated cardiac fibrosis, hypertrophy, loss of ejection fraction, and inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: